Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TSCV in Sub-Saharan Africa
NCT05784701Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2023
- Primary completion
- Jan 2027
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of trivalent salmonella conjugate vaccine in salmonellosis, sponsored by University of Maryland, Baltimore. Started Apr 2023; status: active, not recruiting.
02
Drugs
trivalent salmonella conjugate vaccine
03
Conditions
salmonellosis
Beyond the preview
Go deeper on NCT05784701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784701.